Curadel Surgical Innovations

What Curadel Surgical Innovations does

Curadel Surgical Innovations, Inc. (d/b/a Curadel Pharma) is a privately held, Delaware-incorporated clinical-stage biopharmaceutical company founded in 2014 and headquartered in Bonita Springs, Florida. The company is built around a proprietary zwitterionic chemistry platform that underpins two distinct therapeutic and imaging programs: (1) Audacious Alpha™, a pan-tumor targeted alpha therapy (TAT) platform designed to treat challenging metastatic cancers while preventing tumor regrowth, resistance, and collateral damage to healthy tissues; and (2) ZW800-1 (nizaracianine triflutate), a first-in-class zwitterionic optical imaging agent currently in a Phase 3 pivotal study to highlight the ureter during abdominopelvic surgery. The company's founder and CEO, John Frangioni, is publicly described as a recognized pioneer in zwitterionicity, and the leadership team is positioned as experts in radiopharma.

The company has no commercial products and does not currently generate revenue. Its intended business model is enterprise B2B: securing corporate partnerships, licensing agreements, and co-development deals with larger pharmaceutical companies, with eventual distribution through standard pharmaceutical channels upon regulatory approval. End-customer segments in the long term are patients with metastatic cancers that have failed conventional radiation therapy, and surgical oncologists/hospital operating departments performing abdominopelvic procedures that require enhanced ureter visualization. Marketing and customer development are conducted primarily through the company website and direct partnership outreach. Funding to date has come through a series of SEC-registered exempt securities offerings and a Series A2 round, totaling approximately $34 million raised across 2023–2025 to advance clinical development.

Name

Curadel Surgical Innovations

Legal name

Curadel Surgical Innovations, Inc.

Website

https://curadelsurgicalinnovations.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Curadel Surgical Innovations (d/b/a Curadel Pharma) is a clinical-stage biopharmaceutical company developing proprietary zwitterionic radiopharmaceuticals for targeted alpha therapy in metastatic cancers and optical imaging agents for surgical navigation, currently advancing a Phase 3 ureter visualization drug.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Nephrology & Urology Pharmaceuticals (HLAIAAAM), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Radiopharmaceuticals
• Targeted alpha therapy
• Optical surgical navigation
• Cancer radiotherapy drugs
• Zwitterionic imaging agents

Headquarters

HQ city

Natick

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development and Licensing: As a clinical-stage biopharmaceutical company, Curadel Surgical Innovations generates value through development of novel drug candidates for cancer treatment and surgical imaging. Revenue will be generated through licensing agreements, co-development partnerships, and eventual product commercialization in the pharmaceutical space.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Curadel Surgical Innovations (d/b/a Curadel Pharma) is a clinical-stage biopharmaceutical company that develops proprietary zwitterionic radiopharmaceuticals. Its core offerings include the Audacious Alpha™ platform for targeted alpha therapy (TAT) in metastatic cancers and ZW800-1 (nizaracianine triflutate), a first-in-class optical surgical navigation contrast agent currently in Phase 3 trials for ureter visualization during abdominopelvic surgery.

Product overview

Curadel Pharma (d/b/a Curadel Surgical Innovations, Inc.) operates as a radiopharmaceutical innovator with two core products: Audacious Alpha*™* and ZW800-1. Audacious Alpha*™* is a zwitterionic radiotherapy platform designed for targeted alpha therapy to treat challenging metastatic cancers by preventing tumor resistance. ZW800-1 is a first-in-class optical surgical navigation drug currently in Phase 3 trials for highlighting the ureter during surgery. Both products leverage the company's proprietary zwitterionic technology to improve therapeutic windows and reduce collateral damage.

Differentiator

Problem solved

Functional benefit

Brands

• Audacious Alpha*™*: Leveraging proprietary zwitterionic technology to deliver best-in-class outcomes for targeted alpha therapy (TAT).

Products and services

• Audacious Alpha™ A proprietary zwitterionic radiotherapy platform leveraging targeted alpha therapy (TAT) to deliver best-in-class outcomes. The platform prevents tumor regrowth and resistance while minimizing collateral damage to healthy tissues, targeting a range of challenging metastatic cancers.
• ZW800-1 (nizaracianine triflutate) A first-in-class zwitterionic drug for optical surgical navigation, designed to highlight the ureter during abdominopelvic surgery. Currently in Phase 3 pivotal study.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Lantheus Holdings: Radiopharmaceutical-focused company developing and commercializing diagnostic and therapeutic radiopharmaceuticals, including approved imaging agents. Directly comparable to Curadel's radiopharma platform focus and intraoperative/imaging agent ambitions.
• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with a pipeline of diagnostic and therapeutic radioligands across oncology. Closely parallels Curadel's TAT and imaging drug strategy.
• Bracco Imaging: Specialist in diagnostic imaging agents including contrast media and optical imaging products used intraoperatively. Closely comparable to Curadel's ZW800-1 optical surgical navigation indication.

Broad incumbents

• Novartis (Radioligand Therapy): Large pharma with the most advanced commercial radioligand therapy franchise (Pluvicto, Lutathera) directly competing in TAT and adjacent indications. Sets the commercial benchmark for radiopharma approvals and market access.
• Bayer (Radiopharmaceuticals): Global pharma with approved radiopharmaceutical Xofigo (radium-223) and broader oncology franchise. Represents an incumbent competitive threat and potential acquirer of Curadel-style TAT platforms.
• Stryker (Surgical Visualization / SPY-PHI): Major surgical equipment vendor with intraoperative fluorescence imaging systems (SPY-PHI) used to visualize anatomy during abdominopelvic procedures. Directly addresses the surgical-navigation use case Curadel's ZW800-1 targets.
• Intuitive Surgical (Firefly): Robotic surgery incumbent whose Firefly fluorescence imaging system visualizes anatomy during robotic-assisted abdominopelvic procedures. Competes with ZW800-1's ureter-highlighting indication in the surgical navigation market.

Emerging players

• Point Biopharma (now Eli Lilly): Pre-acquisition Point Biopharma was a clinical-stage radiopharmaceutical developer of PSMA-targeted and alpha-emitting therapies; relevant comparable for Curadel's targeted alpha therapy platform ambitions.
• ITM Isotope Technologies Munich: Developer of targeted radionuclide therapies and medical radioisotopes with a focus on actinium-225 supply. Comparable on TAT platform technology and isotope supply chain relevance.

Others

• Curium (Cardinal Health radiopharma): Largest North American radiopharmaceutical manufacturer supplying diagnostic and therapeutic nuclear medicine products. Comparable as a radiopharma infrastructure peer and potential manufacturing/distribution partner for Curadel.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curadel Surgical Innovations